ClinicalTrials.gg
Not yet recruitingNCT07942077Updated Nov 17, 2026

FLASH Biomarker Study

An observational study in Head and Neck Cancer, sponsored by Abramson Cancer Center at Penn Medicine. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Abramson Cancer Center at Penn Medicine · Observational

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
10
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Head and Neck Neoplasms by Abramson Cancer Center at Penn Medicine — 3 open to participants now, 5 under way, none of them phase 3. Head and Neck Neoplasms · Abramson Cancer Center at Penn Medicine.

Started
2026
with 1 other
Observational
2 of 13
1 open now
Registered
13th of 13
by date

Among the 13 studies in Head and Neck Neoplasms by Abramson Cancer Center at Penn Medicine, this one is one of 2 that started in 2026, is one of 2 observational ones, and was the 13th registered.

Head and Neck Neoplasms

2,714 studies on the registry are indexed under Head and Neck Neoplasms; 597 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

3 of the 13 studies in Head and Neck Neoplasms by Abramson Cancer Center at Penn Medicine are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Head and Neck Neoplasms by Abramson Cancer Center at Penn Medicine, or all of them as a file.
02

Study summary

This is a single-center, non-interventional biospecimen collection protocol that accompanies C-FLASH-01 (Protocol IBA-04-UP, IDE G260113), a pilot trial of ultra-high dose rate proton reirradiation (ConformalFLASH) for head and neck cancer. Blood and saliva will be collected from up to 10 participants enrolled on the C-FLASH-01 trial at three time points: 1) within 4 weeks before the start of radiotherapy, 2) within 3 days of the last day of radiotherapy, and 3) within 4 months after completion of radiotherapy.

Read the detailed description

The study team hypothesize that biomarkers measurable in blood and saliva, including but not limited to cell-free DNA and cytokines, change over the course of ConformalFLASH reirradiation and are associated with normal tissue response/toxicity. This protocol does not include a study intervention; all radiotherapy is delivered under the separately approved parent protocol (Protocol IBA-04-UP, IDE G260113).

03

Conditions studied

  • Head and Neck Cancer

Keywords

  • Head and neck Cancer
  • Biomarker
  • Biospecimen
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants are recruited exclusively from among individuals enrolled on C-FLASH-01 (Protocol IBA-04-UP, IDE G260113) in the Department of Radiation Oncology at the University of Pennsylvania. No advertising, flyers, social media, or other external recruitment will be used, and no additional screening of the general population is required.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Enrolled on C-FLASH-01 (Protocol IBA-04-UP, IDE G260113) and planned to receive ConformalFLASH reirradiation
  • Male or female, aged 18 years or older
  • Provision of signed and dated for this biospecimen protocol
  • Stated willingness to comply with the specimen collection

Exclusion criteria

Exclusion Criteria:

  • Any condition that, in the judgment of the investigator, makes repeated peripheral venipuncture unsafe or infeasible
  • Inability to provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
10 participants (estimated)
Target follow-up
3 Weeks
Patient registry
Yes
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Batched analysis of Biomarker dynamics in blood Including but not limited to cell-free DNA and cytokines, following ConformalFLASH reirradiation for up to 10 participants.

    Change in biomarker measures (e.g., cell-free DNA and cytokines) in plasma between baseline, end of radiotherapy, and within 4 months after completion of radiotherapy. At each time point, 16 mL of peripheral blood will be drawn by a trained phlebotomist or delegated study team member into Streck Cell-Free DNA BCT tubes and EDTA tubes. The maximum cumulative volume drawn under this protocol is 48 mL per participant. Streck tubes stabilize cell-free DNA for the cell-free DNA analyses; EDTA tubes provide plasma and buffy coat for cytokine analyses and potential cellular analyses. At every collection - blood will be centrifuged; plasma and buffy coat aliquoted and stored at - 80 °C.

    Time frame: - Collect blood (16 mL) between baseline (Screening, Enrollment, and Baseline) - (Visit 1) - Collect Blood (16 mL) end of Radiotherapy (Visit 2) - Collect Blood (16 mL) within 4 months after completion of radiotherapy (Post-Radiotherapy) - (Visit 3)

  2. Batched analysis of Biomarker dynamic in the saliva including but not limited to cell-free DNA and cytokines, following ConformalFLASH reirradiation for up to 10 participants.

    Change in biomarker measures (e.g., cell-free DNA and cytokines) in saliva between baseline, end of radiotherapy, and within 4 months after completion of radiotherapy. At each time point, saliva will be collected into a commercial saliva collection tube in accordance with the manufacturer's instructions, after the 30-minute interval. At every collection - Saliva will be stored at - 80 °C.

    Time frame: - Between baseline (Screening, Enrollment, and Baseline Collection) - (Visit 1) - End of Radiotherapy Collection (Visit 2) - Within 4 months after completion of radiotherapy (Post-Radiotherapy Collection) - (Visit 3)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2029, 36 months later.

Of 215 non-industry observational studies under Head and Neck Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 144. This study's planned 36 months is below that.

Counting every sponsor, half of 237 studies reached it within 71 months; a quarter within 29 and three quarters within 144.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2026
First posted
Nov 17, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Nov 1, 2029
CompletionEst.
Nov 1, 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942077
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Nov 1, 2029 (estimated)
Completion
Nov 1, 2029 (estimated)
Last update
Nov 17, 2026

Study contacts

Ching Lai
Contact
Ching.Lai@pennmedicine.upenn.edu
267-250-9244
Karen Tang
Contact
Karen.Tang1@Pennmedicine.upenn.edu
267-299-9618
Shervin Tabrizi, MD
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion